RemeGen Co Ltd Class H 09995
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$77.10
- Day Range
- HK$70.60–77.10
- 52-Week Range
- HK$63.30–126.60
- Bid/Ask
- HK$72.85 / HK$72.90
- Shares Outstanding
- 564.22M
- Market Cap
- HK$41.13B
- Volume/Avg
- 949,394 / 4M
Key Statistics
- Price/Earnings (Normalized)
- 6.85
- Price/Sales
- 4.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 3,146
- Website
- https://www.remegen.com
Valuation
|
Metric
|
09995
|
|---|---|
Price/Earnings (Normalized) | 6.85 |
Price/Book Value | 4.53 |
Price/Sales | 4.83 |
Price/Cash Flow | 8.27 |
Price/Earnings
09995
Financial Strength
|
Metric
|
09995
|
|---|---|
Quick Ratio | 4.19 |
Current Ratio | 4.82 |
Interest Coverage | 126.75 |
Quick Ratio
09995
Profitability
|
Metric
|
09995
|
|---|---|
Return on Assets (Normalized) | 57.12% |
Return on Equity (Normalized) | 91.78% |
Return on Invested Capital (Normalized) | 67.44% |
Return on Assets
09995
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Ym#<l!K | LOCK|<!c@$ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|w^h!$@@ | LOCK|<%rPF | $76B | |||
| Moderna Inc
MRNA
| LOCK|jM$ygJ | LOCK|%> | $75B | |||
| argenx SE ADR
ARGX
| LOCK|Y@!Lx#@ | LOCK|Q& | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!&&@HK | LOCK|!@T | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|F$v@GY | LOCK|f^&$ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@s?NwZM | LOCK|PJh$> | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|Xh#&b^ | LOCK|^& | $24B | |||
| Incyte Corp
INCY
| LOCK|&n<^Ch | LOCK|%G& | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?B&FX<n | LOCK|hNM | $15B |
United States